These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28473598)

  • 1. Test-Retest Variability in Lesion SUV and Lesion SUR in
    Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
    J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.
    Markovina S; Duan F; Snyder BS; Siegel BA; Machtay M; Bradley JD
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):597-605. PubMed ID: 26461002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A convolutional neural network for fully automated blood SUV determination to facilitate SUR computation in oncological FDG-PET.
    Nikulin P; Hofheinz F; Maus J; Li Y; Bütof R; Lange C; Furth C; Zschaeck S; Kreissl MC; Kotzerke J; van den Hoff J
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):995-1004. PubMed ID: 33006022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test-Retest Repeatability of Patlak Slopes versus Standardized Uptake Values for Hypermetabolic Lesions and Normal Organs in an Oncologic PET/CT Population.
    Ince S; Laforest R; Ashrafinia S; Smith AM; Wahl RL; Fraum TJ
    Mol Imaging Biol; 2024 Apr; 26(2):284-293. PubMed ID: 38466523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical PERCIST and 25% of SUV
    Savaikar MA; Whitehead T; Roy S; Strong L; Fettig N; Prmeau T; Luo J; Li S; Wahl RL; Shoghi KI
    J Nucl Med; 2020 Jun; 61(6):842-849. PubMed ID: 31757841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?
    Ince S; Laforest R; Itani M; Prasad V; Derenoncourt PR; Crandall JP; Ashrafinia S; Smith AM; Wahl RL; Fraum TJ
    J Nucl Med; 2024 Sep; 65(9):1349-1356. PubMed ID: 39142828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Time-of-Flight and Regularized Reconstructions on Quantitative Measurements and Qualitative Assessments in Newly Diagnosed Prostate Cancer With
    Behr SC; Mollard BJ; Yang J; Flavell RR; Hawkins RA; Seo Y
    Mol Imaging; 2017; 16():1536012117736703. PubMed ID: 29169313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiquantitative analysis of cerebral [
    Cruz-Cortes Á; Avendaño-Estrada A; Alcauter S; Núñez-Enríquez JC; Rivera-Bravo B; Olarte-Casas MÁ; Ávila-Rodríguez MÁ
    Pediatr Radiol; 2023 Dec; 53(13):2574-2585. PubMed ID: 37910188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test-retest repeatability of quantitative bone SPECT/CT.
    Yamane T; Fukushima K; Shirotake S; Nishimoto K; Okabe T; Oyama M; Seto A; Kuji I
    Ann Nucl Med; 2021 Mar; 35(3):338-346. PubMed ID: 33400148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved identification of tumors in 18F-FDG-PET examination by normalizing the standard uptake in the liver based on blood test data.
    Alam MA; Hanaoka S; Nomura Y; Kikuchi T; Nakao T; Takenaga T; Hayashi N; Yoshikawa T; Abe O
    Int J Comput Assist Radiol Surg; 2024 Mar; 19(3):581-590. PubMed ID: 38180621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative test-retest variability of outcome parameters derived from brain [18F]FDG PET studies in non-human primates.
    Goutal S; Tournier N; Guillermier M; Van Camp N; Barret O; Gaudin M; Bottlaender M; Hantraye P; Lavisse S
    PLoS One; 2020; 15(10):e0240228. PubMed ID: 33017429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigating SUV uncertainties using total body PET imaging.
    Smith CLC; Zwezerijnen GJC; den Hollander ME; Weijland J; Yaqub M; Boellaard R
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1070-1078. PubMed ID: 37953391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy.
    Kinahan PE; Perlman ES; Sunderland JJ; Subramaniam R; Wollenweber SD; Turkington TG; Lodge MA; Boellaard R; Obuchowski NA; Wahl RL
    Radiology; 2020 Mar; 294(3):647-657. PubMed ID: 31909700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing SUV Analysis: A Multicenter Study on Preclinical FDG-PET/CT Highlights the Impact of Standardization.
    Kuntner C; Alcaide C; Anestis D; Bankstahl JP; Boutin H; Brasse D; Elvas F; Forster D; Rouchota MG; Tavares A; Teuter M; Wanek T; Zachhuber L; Mannheim JG
    Mol Imaging Biol; 2024 Aug; 26(4):668-679. PubMed ID: 38907124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the quarter-dose 18 F-FDG total-body PET in routine clinical practice and its clinical value.
    Zhao M; Zan K; Cui X; Chai L; Ge M; Cheng Z; Sun H; Duan Y
    Nucl Med Commun; 2023 Dec; 44(12):1176-1183. PubMed ID: 37901913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.
    Meyer HJ; Wienke A; Surov A
    PLoS One; 2019; 14(6):e0217781. PubMed ID: 31206524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping
    Wu Q; Gu F; O'Suilleabhain LD; Sari H; Xue S; Shi K; Rominger A; O'Sullivan F
    J Nucl Med; 2024 Jun; 65(6):971-979. PubMed ID: 38604759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-acquisition Standardization of Positron Emission Tomography Images.
    Mortazi A; Udupa JK; Odhner D; Tong Y; Torigian DA
    Res Sq; 2023 Jan; ():. PubMed ID: 36711962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-order non-spatial effects dominate second-order spatial effects in the texture quantifier analysis of 18F-FDG-PET images.
    Brooks FJ; Grigsby PW
    PLoS One; 2015; 10(2):e0116574. PubMed ID: 25714472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [
    Wehlte L; Walter J; Daisenberger L; Kuhnle F; Ingenerf M; Schmid-Tannwald C; Brendel M; Kauffmann-Guerrero D; Heinzerling L; Tufman A; Pfluger T; Völter F
    Diagnostics (Basel); 2024 May; 14(11):. PubMed ID: 38893665
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.